The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Lung ART: investigating the role of postoperative radiotherapy in completely resected N2 NSCLC
Lizza Hendriks, MD, PhD, Maastricht University, Maastricht, Netherlands, discusses the Phase III Lung ART (NCT00410683) clinical trial evaluating post-operative radiotherapy in completely resected N2 non-small cell lung cancer (NSCLC). Prior to the Lung ART study, the role of postoperative radiotherapy remained controversial due to a lack in appropriate clinical trial data. Overall, the results indicated ruling out the use of postoperative radiotherapy for the treatment of completely resected N2 NSCLC. This interview took place during the virtual European Lung Cancer Congress 2022.
